This KS Myeloid cell meeting aims to bring together key leaders in academia and industry to discuss recent insights regarding myeloid cell functional heterogeneity and how we should be thinking about targeting these cells for therapeutic interventions. It is clear that myeloid cells hold significant therapeutic promise, but at this moment, this largely remains to be realised. As such, previous meetings have typically focused on academic advances, however we firmly believe that by bringing together all actors we can further stimulate discussion, collaboration and ultimately move the field forward. Therefore with this meeting, we hope to provide both an update of ongoing academic research and the latest novel therapeutic approaches being applied in industry. One of the main areas of focus for the meeting will be on how we can translate recent seminal single cell studies into meaningful biology. Specifically, we will focus on how we can make sense of the recent single cell RNA-seq studies which have identified both unique and conserved myeloid cell populations across tissues and diseases. While these studies have moved the field forward, confusion has stemmed from the variety of names given to similar populations thus here we aim to start to align these studies. This will be achieved through a panel discussion and through the different invited talks and workshops covering selected abstracts. Finally, we hope to provide novel insight for junior scientists regarding how science is conducted in both industrial and academic settings as well as shedding light on the process of therapy discovery and development.